Company Performance Metrics
Zhen Su: Head of Global Medical Affairs - Oncology
Jasmine Greenamyer: Vice President, Global Strategic PartnershipsPast Role: Colorectal Cancer Alliance, Chief Operating Officer
EMD Serono, Inc. discovers and develops biopharmaceutical products. The company focuses on specialized areas, such as neurodegenerative diseases, fertility, and metabolic endocrinology, as well as oncology. It offers GONAL-f RFF Pen, a pre-filled and ready-to-use multi-dose FSH for the treatment of infertility; Ovidrel PreFilled Syringe, a
ready-to-inject liquid infertility treatment; Luveris, a recombinant human luteinizing hormone; and Cetrotide, an gonadotropin releasing hormone antagonist. The company also provides Saizen for growth hormone deficiency in children and adults; Serostim for HIV-associated wasting; Zorbtive for short bowel syndrome; and Rebif for the treatment of relapsing remitting multiple sclerosis (MS). In addition, it offers Fertility LifeLines, an educational service that offers customized information and support to individuals at various stages of the patient journey. The company offers its products through distributors. It has strategic alliances with Newron Pharmaceuticals, SpA; ZymoGenetics, Inc.; Pfizer Inc.; Brigham and Women's Hospital; and CuraScript, Inc. EMD Serono, Inc. was formerly known as Serono, Inc. and changed its name to EMD Serono, Inc. in January 2007. The company is based in Rockland, Massachusetts. EMD Serono, Inc. operates as a subsidiary of Merck Serono S.A.
